OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’
State on share capital and voting rights (FR)
You confirm that you have read our privacy policy. You can unsubscribe at any time by using the unsubscribe links.